*All Times Shown are in Eastern Daylight Time*

Exploring the Emerging Consensus on Which Biomarker is the Most Useful for IPF Drug Development
Morning Plenary Moderator: Tushar Desai, Assistant Professor, Standford University Medical Center

9:00 am Virtual Coffee & Networking

9:30 am Providing an Update on IPF Biomarkers: Uncovering the Emerging Consensus on Which Biomarker Best Predicts Disease Progression to Help Maximize the Success of Your ILD Therapeutic in a Clinical Setting

  • Andrew Thorley Fibrosis Therapeutic Area Lead - OMNI Biomarker Development , Genentech


  • Reviewing findings from previous clinical trials
  • Emerging biological and digital biomarkers
  • Health equity in biomarker development

10:00 am Clinical relevance of extracellular matrix remodeling biomarkers to aid personal medicine


• Assessing ECM remodeling non-invasively can be used as prognostic and
pharmacodynamic biomarkers
• Biomarkers of tissue formation and degradation provide essential and
different types of information
• The difference between assessing remodeling of the basement membrane
versus the interstitial matrix during disease progression

10:30 am Early Disease Detection for Pulmonary Fibrosis: What Genetics & Protein Biomarker Studies Can Teach Us about IPF Disease Pathogenesis.

  • Gary Matthew Hunninghake Associate Professor of Medicine , Harvard Medical School


  • Why we should direct efforts towards early disease detection.
  • What genetic studies of early disease can teach us about IPF pathogenesis
  • What protein biomarker studies can teach us about IPF pathogenesis.
  • Planning for future interventional studies in early disease.

11:00 am Patient Response to Available Therapies & Optimize Your IPF Treatment Plan


• Clinical parameters and biological markers helpful to predict prognosis and response to treatment
• Towards a more “personalized” medical approach to IPF patients
• Immunological features and different responses to antifibrotic treatments

11:30 am Morning Break & Networking

Preclinical & Early Translational Track

Late Translational & Clinical Track

Deep Diving Into the Fibrotic Lung Microenvironment in the Context of IPF Therapeutics

Track Moderator: Robert Kaner,MD, Cornell University

A Translational Journey: Investigating Endpoints & Imaging in the Context of IPF Drug Development

Track Moderator: Jessica Shore, Vice President - Research & Programs, Pulmonary Fibrosis Foundation

12.00 Dissecting the Modified Lung Microenvironment in IPF Patients & Analyzing Which Biological Factors Linked to IPF Pathology to Manipulate Them for IPF Drug Development

Lisa Hazelwood, Principal Research Scientist Immunology & Fibrosis, AbbVie

12.00 Inhaled Galectin-3 Inhibition in severe lung disease like IPF and Covid-19 – is it feasible and what benefit can you expect?

Bertil Lindmark, Chief Medical Officer, Galecto

12.30 Elucidating the Role of the Endothelium in the Context of IPF Drug Development

Rachel Knipe, Instructor in Medicine, Massachusetts
General Hospital

12.30 Revealing Radiology of Progressive Fibrosis

Mary Salvatore, Associate Professor Thoracic Radiology, Columbia University Medical Center

1.00 Investigating the Role of an Altered ECM Landscape in Idiopathic Pulmonary Fibrosis

Ulf Hedstrom, Senior Research Scientist, AstraZeneca

1.00 Spotlight on IPF Imaging: Examining Novel Imaging Modalities to Identify Fibrotic Progression in IPF Patients

Kristoffer Ostridge, Physician Director, AstraZeneca

1.30 End of Track

1.30 Hyperpolarized 129Xenon MRI: The Next Frontier in Pulmonary Functional Imaging

Bastiaan Driehuys, PhD, Founder and Chief Technology Officer, Polarean Imaging

2:00 pm Lunch & Networking

Exploring Emerging Therapeutics & Treatment Strategies for IPF

3:00 pm Dissecting the Mechanisms of Epithelial Dysfunction in IPF Patients & Revealing How This Relates to IPF Pathology


  • Review human genetic and biological data regarding changes in IPF epithelium
  • Highlight lessons learned from animal and cell culture models
  • Discuss the epithelium as a novel therapeutic target for reversing fibrosis

3:30 pm Understanding the Microbial Metabolic Drivers of Epithelial Cell Dysfunction in IPF

  • Philip Molyeanux Clinical Senior Lecturer in Interstitial Lung Disease, Imperial College London


  • Review data on the metabolic environment of the airways in IPF
  • Discuss how metabolites can effect epithelial cell and fibroblast function
  • Discuss how these pathways could be targeted

4:00 pm Inhaled Biologics: The Application of Anticalins in the Treatment of IPF


• Current therapeutics and the unmet need in IPF
• Benefits of local intervention via inhalation versus systemic administration
• Inhaled Anticalin antagonists for respiratory disease

Discovering How to Design & Execute a Fool Proof Plan to Successfully Identify & Validate New Targets for IPF

4:30 pm Uncovering Targeted Drug Delivery to Improve Efficacy in IPF


• Understanding the importance of rapid organ delivery
• Exploring reduced serum exposure in the context of IPF drug targeting
• Exploring increased safety/reduced off target toxicity

5:00 pm Antibody Mediated Blockade of Interleukin-11 signaling for IPF and Other Fibrosing Lung Diseases

  • James Swaney Vice President - Fibrosis & Translational Biology , Lassen Therapeutics


  • Upregulation of IL11 in lung fibrosis
  • Development and characterization of anti-IL11 receptor antibodies to treat lung fibrosis
  • Using primary cells, in vivo models and ex vivo translational assays to interrogate anti-IL11 therapy as a treatment for lung fibrosis

5:30 pm Revealing Breakthrough Mitochondrial Science for IPF


  • Analyze how CohBar is harnessing the power of mitochondria peptides to target a wide range of chronic and age-related diseases associated with mitochondrial dysfunction, including IPF
  • Review CohBar’s clinical candidate, CB5138-3, in development for IPF which has demonstrated positive effects including reduction of fibrosis, inflammation, and collagen deposition.
  • Discuss other potential antifibrotic indications for CB5138-3

Investigating IPF Genetics

6:00 pm Next Generation Targeting in the Lung

  • Samir Ounzain Co-Founder & Chief Executive Officer, HAYA Therapeutics


  • New concepts for identifying and validating targets in the lung
  • Exploiting the dark side of your genome for next generation antifibrotic therapies in the lungs
  • Discovering your unique target profile

6:30 pm Pulmonary fibrosis: No Easy Way Out of EZH2


• Chronic TGFβ1 treatment induces nuclear translocation of TAK1.
• EZH2 is liberated from PRC2 by TAK1-mediated phosphorylation, accompanied by an EZH1 switch to maintain H3K27me3 deposition at non-target genes.
• Liberated EZH2 forms a transcriptional complex with nuclear actin and RNA polymerase II to fine-tune pro-fibrotic gene expression.

7:00 pm Conference End